5 Potential Takeover Targets with Strong Price Momentum

4. Organon & Co. (NYSE:OGN)

Organon & Co. (NYSE:OGN) is one of the 10 potential takeover targets with strong price momentum. Around April 10–13, 2026, reports emerged that Sun Pharmaceutical Industries had submitted a binding offer to acquire the company in a deal valued at roughly $10 billion to $12 billion. The market reaction was immediate. Organon shares surged about 28% in a single session and had risen nearly 39% over the week following the reports, marking one of the sharpest moves tied to takeover speculation this year.

That reaction reflects how the market is pricing in the strategic value of the business rather than its current financial profile. Organon, which was spun off from Merck & Co. in 2021, has a portfolio spanning women’s health, biosimilars, and established medicines, including contraceptive and fertility products such as Nexplanon and NuvaRing. The company’s scale and product base make it a plausible target for a strategic buyer looking to expand internationally or deepen exposure to women’s health.

Organon & Co. (NYSE:OGN) is a global healthcare company focused on women’s health, biosimilars, and a portfolio of established medicines.